מגאקסין IV ישראל - עברית - Ministry of Health

מגאקסין iv

bayer israel ltd - moxifloxacin as hydrochloride - תמיסה לאינפוזיה - moxifloxacin as hydrochloride 1.6 mg/ml - moxifloxacin - moxifloxacin - megaxin iv is indicated for the treatment of adults (> 18 years of age) with community acuired pneumonia caused by streptococcus pneumoniae, haemophilus influenzae, moraxella catarrhalis, staphylococcus aureus, klebsiella pneumoniae, mycoplasma pneumoniae or chlamydia pneumoniae and complicated skin and skin structure infections caused by methicillin susceptible staphylococus aureus, escherichia coli, klebsiella pneumoniae or enterobacter cloacae. appropriate culture and susceptibility tests should be performed before treatment in order to isolate and identify organisms causing infection and to determine their susceptibility to moxifloxacin. therapy with megaxin may be initiated before results of these tests are known; once results become available ,appropriate therapy should be continued.

ויגהמוקס ישראל - עברית - Ministry of Health

ויגהמוקס

novartis israel ltd - moxifloxacin as hydrochloride - תמיסה לעין - moxifloxacin as hydrochloride 0.5 % - moxifloxacin - moxifloxacin - for the treatment of bacterial conjunctivitis caused by susceptible strains or organisms.

מגאקסין טבליות ישראל - עברית - Ministry of Health

מגאקסין טבליות

bayer israel ltd - moxifloxacin as hydrochloride - טבליות מצופות פילם - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections: respiratory infections: bronchitis: acute exacerbation of chronic bronchitis ; pneumonia: community acquired ; sinusitis: acute uncomplicated; community-acquired spontaneous and wound infections of the skin and skin structure.

מגאקסין טבליות ישראל - עברית - Ministry of Health

מגאקסין טבליות

bayer israel ltd - moxifloxacin as hydrochloride - טבליות מצופות פילם - moxifloxacin as hydrochloride 0.4 g - moxifloxacin - moxifloxacin - for the treatment of the following bacterial infections: respiratory infections: bronchitis: acute exacerbation of chronic bronchitis ; pneumonia: community acquired ; sinusitis: acute uncomplicated; community-acquired spontaneous and wound infections of the skin and skin structure.

ציפרופלוקסצין טבע 500 מג ישראל - עברית - Ministry of Health

ציפרופלוקסצין טבע 500 מג

teva israel ltd - ciprofloxacin as hydrochloride - טבליה - ciprofloxacin as hydrochloride 500 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

ציפרופלוקסצין טבע 250 מג ישראל - עברית - Ministry of Health

ציפרופלוקסצין טבע 250 מג

teva pharmaceutical industries ltd, israel - ciprofloxacin as hydrochloride - טבליה - ciprofloxacin as hydrochloride 250 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

ציפרופלוקסצין טבע 750 מג ישראל - עברית - Ministry of Health

ציפרופלוקסצין טבע 750 מג

teva pharmaceutical industries ltd, israel - ciprofloxacin as hydrochloride - טבליה - ciprofloxacin as hydrochloride 750 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

ציפרודקס 500 ישראל - עברית - Ministry of Health

ציפרודקס 500

dexcel ltd, israel - ciprofloxacin as hydrochloride - קפליות - ciprofloxacin as hydrochloride 500 mg - ciprofloxacin - ciprofloxacin - broad spectrum antibiotic for infections caused by ciprofloxacin sensitive pathogens: invasive infections of the external ear. treatment of acute pulmonary exacerbation of cystic fibrosis associated with p. aeruginosa infections in pediatric patients aged 5-17 years.

סילוקסן ישראל - עברית - Ministry of Health

סילוקסן

novartis israel ltd - ciprofloxacin as hydrochloride - תמיסה - ciprofloxacin as hydrochloride 3 mg/ml - ciprofloxacin - ciprofloxacin - corneal ulcers and conjunctivitis caused by susceptible gram positive and gram negative microorganisms for adults and pediatric patients above the age of 1 year. for localized or diffuse otitis externa accompanied by a strong inflammatory reaction and of which the strains are susceptible to ciprofloxacin, and for the acute flare-up of a chronic otitis media. in this case, a mucopurulent secretion comes through the perforated eardrum. pseudomonas aeruginosa is one of the organisms most likely to be found in this case. also in other infections of the ear in which pseudomonas aeruginosa and/or other susceptible strains may be demonstrated or suspected (for example with suppurating tympanic tubes), ciloxan can be used under the strict supervision of an ear specialist. it must be understood that this is not a routine treatment and that improper use must be avoided.

אופלוקסצין טבע 200 מג ישראל - עברית - Ministry of Health

אופלוקסצין טבע 200 מג

abic ltd. - ofloxacin - טבליה - ofloxacin 200 mg - ofloxacin - ofloxacin - bacterial infections due to ofloxacin-susceptible microorganisms, such as:- acute, chronic, or recurrent lower respiratory tract infections (bronchitis) pneumonia (not for the treatment of first choice in pnemonia caused by pneumococci). - chronic and recurrent infections of the ear, nose, and throat. ofloxacin is in general not indicated for the treatment of acute tonsillitis caused by betahaemolytic streptococci. - infections of soft tissues and skin. - infections of the bones and joints. - abdominal infections including infections in the pelvis minor and bacterial enteritis. - infections of the kidney, urinary tract, and genital organs, gonorrhoea.prevention of infections due to ofloxacin-susceptible pathogens in patients with a significant reduction in resistance to infections (e.g. in neutropenic state).